Kevin T Nead1, Ninjin Boldbaatar2, David D Yang2, Sumi Sinha2, Paul L Nguyen2. 1. Department of Radiation Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. Electronic address: Kevin.Nead@uphs.upenn.edu. 2. Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Abstract
OBJECTIVES: To investigate the association of androgen deprivation therapy (ADT) for prostate cancer with thromboembolic events. METHODS: PubMed, Web of Science, and Scopus were queried on April 5, 2017 for systematic review. Additionally, The World Health Organization International Trials Registry Platform was queried on June 23, 2017. Eligible studies reported thromboembolic events among individuals with prostate cancer exposed to ADT vs a lesser-exposed group. Five hundred sixty-nine unique studies were identified with 65 undergoing full-text review. We utilized the Meta-analysis of Observational Studies in Epidemiology statement guidelines and the Cochrane Review Group's data extraction template. Study quality was evaluated by Newcastle-Ottawa Scale criteria. We conducted random-effects meta-analyses to calculate summary statistic risk ratios and 95% confidence intervals. Heterogeneity was quantified using the I2 statistic. Small study effects were evaluated using Begg and Egger statistics. RESULTS: In 10 studies "ADT without estrogen" increased the risk of thromboembolic events (risk ratio [RR] 1.43, 95% confidence interval [CI] 1.15-1.77, P = .001). In 9 studies estrogen therapy alone was associated with an increased risk of thromboembolic events (RR 3.72, 95% CI 1.78-7.80, P <.001). We found an increased risk of thromboembolic events from ADT use without estrogen when limited to localized disease (RR 1.10, 95% CI 1.05-1.16, P <.001). Heterogeneity was resolved in those studies examining localized disease. There was no evidence of small study effects. CONCLUSION: The currently available evidence suggests that ADT without estrogen is associated with an increased the risk of thromboembolic events.
OBJECTIVES: To investigate the association of androgen deprivation therapy (ADT) for prostate cancer with thromboembolic events. METHODS: PubMed, Web of Science, and Scopus were queried on April 5, 2017 for systematic review. Additionally, The World Health Organization International Trials Registry Platform was queried on June 23, 2017. Eligible studies reported thromboembolic events among individuals with prostate cancer exposed to ADT vs a lesser-exposed group. Five hundred sixty-nine unique studies were identified with 65 undergoing full-text review. We utilized the Meta-analysis of Observational Studies in Epidemiology statement guidelines and the Cochrane Review Group's data extraction template. Study quality was evaluated by Newcastle-Ottawa Scale criteria. We conducted random-effects meta-analyses to calculate summary statistic risk ratios and 95% confidence intervals. Heterogeneity was quantified using the I2 statistic. Small study effects were evaluated using Begg and Egger statistics. RESULTS: In 10 studies "ADT without estrogen" increased the risk of thromboembolic events (risk ratio [RR] 1.43, 95% confidence interval [CI] 1.15-1.77, P = .001). In 9 studies estrogen therapy alone was associated with an increased risk of thromboembolic events (RR 3.72, 95% CI 1.78-7.80, P <.001). We found an increased risk of thromboembolic events from ADT use without estrogen when limited to localized disease (RR 1.10, 95% CI 1.05-1.16, P <.001). Heterogeneity was resolved in those studies examining localized disease. There was no evidence of small study effects. CONCLUSION: The currently available evidence suggests that ADT without estrogen is associated with an increased the risk of thromboembolic events.
Authors: Kim Edmunds; Haitham Tuffaha; Daniel A Galvão; Paul Scuffham; Robert U Newton Journal: Support Care Cancer Date: 2020-01-07 Impact factor: 3.603
Authors: Andrea Kokorovic; Alan I So; Hosam Serag; Christopher French; Robert J Hamilton; Jason P Izard; Jasmir G Nayak; Frédéric Pouliot; Fred Saad; Bobby Shayegan; Armen Aprikian; Ricardo A Rendon Journal: Can Urol Assoc J Date: 2022-08 Impact factor: 2.052
Authors: Renato D Lopes; Celestia S Higano; Susan F Slovin; Adam J Nelson; Robert Bigelow; Per S Sørensen; Chiara Melloni; Shaun G Goodman; Christopher P Evans; Jan Nilsson; Deepak L Bhatt; Noel W Clarke; Tine K Olesen; Belinda T Doyle-Olsen; Henriette Kristensen; Lauren Arney; Matthew T Roe; John H Alexander Journal: Circulation Date: 2021-08-30 Impact factor: 39.918
Authors: Hsin-Le Lin; Chia-Yi Lee; Jing-Yang Huang; Po-Chen Tseng; Shun-Fa Yang Journal: Int J Environ Res Public Health Date: 2022-02-17 Impact factor: 3.390